HeartSciences Inc. 8-K
Research Summary
AI-generated summary
HeartSciences Inc. Reports Death of COO and Director
What Happened HeartSciences Inc. (filed Form 8-K on April 3, 2026) announced that Mark Hilz, its Chief Operating Officer, Corporate Secretary and a member of the Board of Directors, passed away on April 1, 2026 at age 67 following a period of illness. Mr. Hilz had served on the company’s board since 2013 and as COO and Corporate Secretary since March 2022.
Key Details
- Date of death: April 1, 2026; age 67.
- Tenure: Board member since 2013; COO and Corporate Secretary since March 2022.
- Company statement: Does not anticipate hiring a new COO or replacing the role in the foreseeable future.
- Product/program status: The MyoVista Insights software platform has been launched, and the MyoVista wavECG device was submitted to the FDA in December 2025 for 510(k) premarket clearance; the company does not anticipate changes to its business, operations, or planned commercialization as a result of Mr. Hilz’s passing.
Why It Matters This is an executive leadership and board change for HeartSciences, but the company has told investors it expects operational continuity and no impact to its commercialization plans for the MyoVista products. Retail investors should note the leadership vacancy on the board and the COO role change, but the filing states the company does not plan to replace the COO and believes its FDA submission and product launch efforts remain on track.